ACQUISITIONS (Details) (USD $)	Jun. 30, 2012
Inhibitex, Inc. [Member]
Acquisition [Line Items]
Purchase price paid in cash	$ 2,539,000,000
Acquisition costs	12,000,000
Purchase price allocation - Cash	46,000,000
Purchase price allocation - Marketable securities	17,000,000
Purchase price allocation - In-process research and development	1,875,000,000
Purchase price allocation - Accounts payable	(23,000,000)
Purchase price allocation - Accrued expenses	(10,000,000)
Purchase price allocation - Deferred tax liabilities	(579,000,000)
Purchase price allocation - Total identifiable net assets	1,326,000,000
Purchase price allocation - Goodwill	1,213,000,000
Probability To Regulatory Success Rate utilized	38.00%
In-process research and development valuation discount rate	12.00%
Inhibitex, Inc. [Member] | INX189 [Member]
Acquisition [Line Items]
Purchase price allocation - In-process research and development	1,800,000,000
Amylin Pharmaceuticals, Inc. [Member]
Acquisition [Line Items]
Price per share to be paid in cash to acquire the outstanding shares of acquiree	$ 31.00
Net debt and a contractual payment obligation assumed in an acquisition	1,700,000,000
Purchase price paid in cash	$ 5,300,000,000